Jazz Pharmaceuticals acquires investigational medication for EDS
Jazz Pharmaceuticals has acquired rights to ADX-N05 from Aerial BioPharma, LLC. ADX-N05 is a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy.
While ADX_N05’s mechanism of action is not well understood, the molecule has demonstrated wake-promoting properties in pre-clinical and clinical studies. In two Phase 2 studies, ADX-N05 has demonstrated a statistically significant effect on excessive daytime sleepiness in patients with narcolepsy.
Results from Aerial’s Phase 2a clinical trial evaluating the effectiveness and safety of ADX-N05 for the treatment of excessive daytime sleepiness in adults with narcolepsy were presented at the SLEEP 2013 meeting in Baltimore in June 2013. Results from the Phase 2b study will be submitted for presentation at a future scientific meeting. ADX-N05 has previously been evaluated in several Phase 1 and Phase 2 studies. In those studies, ADX-N05 was generally well-tolerated and demonstrated an acceptable safety profile in more than 500 patients. Jazz is expected to begin discussing their Phase 3 clinical program with the FDA soon.
Read more the entire news release on Jazz’s website.
# # #
Date Created: January 18th, 2014
Last Updated: January 18th, 2014